Anticholinesterases in the treatment of Alzheimer's dementia--the first year's experience in Argyll & Clyde.
The local experience of the introduction of a new anticholinesterase treatment for Alzheimer's dementia is described, including the use of a protocol to introduce the use of these drugs. The results in the first 233 patients seen are reported. The protocol seemed to anticipate SMAC. guidelines and to be easy to operate; the drug appeared to have clear clinical effect.
Hughes
A
A
Renfrewshire Healthcare NHS Trust.
Coulter
F
F
Gillespie
R
R
Livingston
H
H
Phillips
K
K
Quinn
E
E
Rimmer
E
E
Smith
M
M
Walker
A
A
D000203:Activities of Daily Living; D000368:Aged; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D002800:Cholinesterase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002985:Clinical Protocols; D000077265:Donepezil; D005194:Family Practice; D015577:Geriatric Assessment; D005852:Geriatric Psychiatry / Q000592:standards*; D006801:Humans; D007189:Indans / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010880:Piperidines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D012606:Scotland; D013222:State Medicine; D016896:Treatment Outcome
D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D000077265:Donepezil